Peter C Black
Overview
Explore the profile of Peter C Black including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
379
Citations
6973
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Apolo A, Baumann B, Al-Ahmadie H, Ballas L, Bangs R, Brothers K, et al.
Bladder Cancer
. 2025 Mar;
11(1):23523735251319185.
PMID: 40034245
The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)' led...
2.
Schmitz-Drager B, Grossmann H, Goebell P, Kamat A, Black P
Urol Oncol
. 2025 Feb;
43(2):129-131.
PMID: 39986815
Objective: Professor Michael Droller is stepping down as Editor-in-chief of Urologic Oncology: Seminars and Original Investigations, a journal that he co-founded. This manuscript describes his relation with the International Bladder...
3.
Annapureddy D, Taylor J, Kamat A, ODonnell M, Howard J, Tan W, et al.
Eur Urol Focus
. 2025 Feb;
PMID: 39922753
Background And Objective: Current data on bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) do not differentiate outcomes by clinical stage. The purpose of this study is to investigate the role...
4.
Kulkarni G, Black P, Sridhar S, Zlotta A, Shayegan B, Rendon R, et al.
Can Urol Assoc J
. 2025 Feb;
19(1):E1-E16.
PMID: 39899885
No abstract available.
5.
Scilipoti P, Moschini M, Li R, Lerner S, Black P, Necchi A, et al.
Eur Urol
. 2024 Dec;
PMID: 39730299
Background And Objective: Bladder cancer (BCa) imposes a substantial economic burden on health care systems and patients. Understanding these financial implications is crucial for effective resource allocation and optimization of...
6.
Taylor J, Kamat A, Annapureddy D, Khene Z, Howard J, Tan W, et al.
Eur Urol Oncol
. 2024 Dec;
PMID: 39694798
Background And Objective: Non-muscle-invasive bladder cancer (NMIBC) patients treated with additional bacillus Calmette-Guérin (BCG) may become unresponsive to BCG. Recently, sequential intravesical gemcitabine and docetaxel (gem/doce) are being used for...
7.
Stecca C, Chowdhury D, Blais N, Alimohamed N, Wood L, Canil C, et al.
Can Urol Assoc J
. 2024 Dec;
18(12):379-390.
PMID: 39641956
No abstract available.
8.
St-Laurent M, Nikkola J, Bahlburg H, Scurll J, Black P
Eur Urol
. 2024 Nov;
87(3):355-356.
PMID: 39616002
No abstract available.
9.
Villegas E, Lajkosz K, Din S, Kuk C, Chan A, Kwong J, et al.
J Urol
. 2024 Oct;
213(3):295-303.
PMID: 39470318
Purpose: Patients with Ta low-grade (LG) nonmuscle-invasive bladder cancer (NMIBC) rarely develop metastases or die of it. Long-term data are scant and length of follow-up poorly defined. Materials And Methods:...
10.
Reike M, Raggi D, Mercinelli C, Cigliola A, Tateo V, Patane D, et al.
Clin Genitourin Cancer
. 2024 Oct;
22(6):102214.
PMID: 39455338
Purpose: The PURE-01 clinical trial reported the use of neoadjuvant treatment with pembrolizumab prior to radical cystectomy (RC) in patients with muscle-invasive bladder. Specific molecular subtypes and immune signatures were...